<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03007550</url>
  </required_header>
  <id_info>
    <org_study_id>ZSGC-001</org_study_id>
    <nct_id>NCT03007550</nct_id>
  </id_info>
  <brief_title>Study On Safety Of Laparoscopic Total Gastrectomy For Clinical Stage I Gastric Cancer</brief_title>
  <acronym>CLASS02-01</acronym>
  <official_title>Prospective Randomized Controlled Multicenter Clinical Trial For Comparison Of Safety Between Laparoscopic And Open Total Gastrectomy In Patients With Clinical Stage I Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This CLASS02-01 trial is a prospective, multicenter trial for laparoscopic total gastrectomy
      (LTG) and open total gastrectomy (OTG) in patients with clinical stage I
      (T1N0M0、T1N1M0、T2N0M0) gastric cancer. The primary purpose of this study is to evaluate the
      early operative morbidity and mortality and determine the safety of LTG compared with OTG for
      clinical stage I gastric adenocarcinoma. The second purpose is to evaluate the recovery
      course and compare the postoperative hospital stay of the patients enrolled in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is an important health problem, being the fourth most common cancer and the
      third leading cause of cancer-related death worldwide. Age standardized mortality rates for
      gastric cancer are 14.3 per 100 000 in men and 6.9 per 100 000 in women. Incidence shows
      clear regional and sex variations-rates are highest in Eastern Asia, Eastern Europe, and
      South America and lowest in Northern and Southern Africa. More than 679 000 new cases and
      498,000 deaths occur every year in China, and an increasing trend of proximal gastric cancer
      is observed during the past years.

      More than 20 years after the introduction of laparoscopic gastrectomy, many large-scale
      randomized controlled trials have been conducted in Japan (JCOG0912 and JLSSG0901), Korea
      (KLASS01 and KLASS02), and China (CLASS01). These trials are all designed to evaluate the
      non-inferiority of laparoscopic-assisted distal gastrectomy (LADG) to its open counterpart.
      No RCT for laparoscopic total gastrectomy (LTG) exists at this moment. The standardization of
      techniques for esophagojejunal anastomosis in LTG has been difficult even for experienced
      surgeons.

      At present, Japan (JCOG1401), Korea (KLASS03), and Netherlands (STOMACH) have planned or
      launched clinical studies on LTG. China is one of the countries with the highest incidence of
      gastric cancer and surgeons have accumulated extensive experience through CLASS01 study. So,
      it's time for conducting the clinical research on the safety of LTG for gastric cancer.

      This CLASS02-01 trial is a prospective, multicenter trial for LTG and open total gastrectomy
      (OTG) in patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric cancer. The primary
      purpose of this study is to evaluate the early operative morbidity and mortality and
      determine the safety of LTG compared with OTG for clinical stage I gastric adenocarcinoma.
      The second purpose is to evaluate the recovery course and compare the postoperative hospital
      stay of the patients enrolled in this study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early operative morbidity and mortality rate</measure>
    <time_frame>30 days</time_frame>
    <description>The early operative morbidity and mortality are defined as the event observed within 30 days following surgery, including intraoperative and postoperative complications and/or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery course</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation, flatus, liquid diet, and soft diet are used to assess the postoperative recovery course, which is a composite outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>The length of postoperative hospital stay will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Laparoscopic total gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open total gastrectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic total gastrectomy</intervention_name>
    <description>LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma</description>
    <arm_group_label>Laparoscopic total gastrectomy</arm_group_label>
    <other_name>Study group (LTG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open total gastrectomy</intervention_name>
    <description>OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma</description>
    <arm_group_label>Open total gastrectomy</arm_group_label>
    <other_name>Control group (OTG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-75 years；

          2. Primary lesion is pathologically diagnosed as gastric adenocarcinoma, such as
             papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, poorly
             cohesive carcinoma (including signet ring cell carcinoma and other variants), and
             mixed adenocarcinoma;

          3. Clinical stage IA (T1N0M0) or IB (T1N1M0, T2N0M0) (According to AJCC-7th TNM staging
             system);

          4. Tumor located in the upper or middle third of the stomach, and curative resection is
             expected to be achievable by total gastrectomy with D1+/D2-10 lymphadenectomy (also
             apply to multiple primary cancers);

          5. No invasion to Z-line;

          6. BMI (Body Mass Index) ＜ 30 kg/m2;

          7. No history of upper abdominal surgery (except for laparoscopic cholecystectomy);

          8. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy,
             etc.;

          9. No enlargement of splenic hilar lymph nodes;

         10. Preoperative performance status (ECOG，Eastern Cooperative Oncology Group) of 0 or 1;

         11. Preoperative ASA (American Society of Anesthesiologists) scoring: I-III;

         12. Sufficient organ functions;

         13. Written informed consent.

        Exclusion Criteria:

          1. Preoperative examinations indicate that the stage of the disease is stage II/III/IV;

          2. Preoperative examination indicate enlargement of perigastric or retroperitoneal lymph
             nodes (min diameter≥1.0cm);

          3. Women during pregnancy or breast-feeding;

          4. Synchronous or metachronous (within 5 years) malignancies;

          5. Body temperature ≥ 38℃ before surgery or infectious disease with a systemic therapy
             indicated;

          6. Severe mental disease;

          7. Severe respiratory disease;

          8. Severe hepatic and renal dysfunction;

          9. Unstable angina pectoris or history of myocardial infarction within 6 months;

         10. History of cerebral infarction or cerebral hemorrhage within 6 months;

         11. Continuous systemic steroid therapy within 1 month (except for topical use);

         12. Gastric cancer complications (bleeding, perforation, obstruction) that requiring
             emergency surgery;

         13. Patients are participating or have participated in another clinical trial (within 6
             months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihong Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZhongShan hospital FuDan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </reference>
  <reference>
    <citation>Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg. 2010 Mar;251(3):417-20. doi: 10.1097/SLA.0b013e3181cc8f6b.</citation>
    <PMID>20160637</PMID>
  </reference>
  <reference>
    <citation>Chen K, Xu XW, Zhang RC, Pan Y, Wu D, Mou YP. Systematic review and meta-analysis of laparoscopy-assisted and open total gastrectomy for gastric cancer. World J Gastroenterol. 2013 Aug 28;19(32):5365-76. doi: 10.3748/wjg.v19.i32.5365. Review.</citation>
    <PMID>23983442</PMID>
  </reference>
  <reference>
    <citation>Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLASS 01). J Korean Surg Soc. 2013 Feb;84(2):123-30. doi: 10.4174/jkss.2013.84.2.123. Epub 2013 Jan 29.</citation>
    <PMID>23396494</PMID>
  </reference>
  <reference>
    <citation>Nakamura K, Katai H, Mizusawa J, Yoshikawa T, Ando M, Terashima M, Ito S, Takagi M, Takagane A, Ninomiya M, Fukushima N, Sasako M. A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Cancer (JCOG0912). Jpn J Clin Oncol. 2013 Mar;43(3):324-7. doi: 10.1093/jjco/hys220. Epub 2012 Dec 28.</citation>
    <PMID>23275644</PMID>
  </reference>
  <reference>
    <citation>Jeong O, Ryu SY, Choi WY, Piao Z, Park YK. Risk factors and learning curve associated with postoperative morbidity of laparoscopic total gastrectomy for gastric carcinoma. Ann Surg Oncol. 2014 Sep;21(9):2994-3001. doi: 10.1245/s10434-014-3666-x. Epub 2014 Apr 1.</citation>
    <PMID>24687152</PMID>
  </reference>
  <reference>
    <citation>Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, Ryu SW, Cho GS, Song KY, Ryu SY. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014 Mar 1;32(7):627-33. doi: 10.1200/JCO.2013.48.8551. Epub 2014 Jan 27.</citation>
    <PMID>24470012</PMID>
  </reference>
  <reference>
    <citation>Kim HI, Hur H, Kim YN, Lee HJ, Kim MC, Han SU, Hyung WJ. Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study [NCT01283893]. BMC Cancer. 2014 Mar 19;14:209. doi: 10.1186/1471-2407-14-209.</citation>
    <PMID>24646327</PMID>
  </reference>
  <reference>
    <citation>Villanueva MT. Gastric cancer: a master KLASS in laparoscopic gastrectomy. Nat Rev Clin Oncol. 2014 Mar;11(3):119. doi: 10.1038/nrclinonc.2014.18. Epub 2014 Feb 11.</citation>
    <PMID>24514147</PMID>
  </reference>
  <reference>
    <citation>Wada N, Kurokawa Y, Takiguchi S, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Mori M, Doki Y. Feasibility of laparoscopy-assisted total gastrectomy in patients with clinical stage I gastric cancer. Gastric Cancer. 2014 Jan;17(1):137-40. doi: 10.1007/s10120-013-0235-0. Epub 2013 Feb 22.</citation>
    <PMID>23430265</PMID>
  </reference>
  <reference>
    <citation>Byun C, Han SU. Current status of randomized controlled trials for laparoscopic gastric surgery for gastric cancer in Korea. Asian J Endosc Surg. 2015 May;8(2):130-8. doi: 10.1111/ases.12176. Epub 2015 Mar 5. Review.</citation>
    <PMID>25753372</PMID>
  </reference>
  <reference>
    <citation>Hur H, Lee HY, Lee HJ, Kim MC, Hyung WJ, Park YK, Kim W, Han SU. Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer. 2015 May 5;15:355. doi: 10.1186/s12885-015-1365-z.</citation>
    <PMID>25939684</PMID>
  </reference>
  <reference>
    <citation>Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, Koeda K, Yoshida K, Takagane A, Kojima K, Sakuramoto S, Shiraishi N, Kitano S. A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901). World J Surg. 2015 Nov;39(11):2734-41. doi: 10.1007/s00268-015-3160-z.</citation>
    <PMID>26170158</PMID>
  </reference>
  <reference>
    <citation>Katai H. Current status of a randomized controlled trial examining laparoscopic gastrectomy for gastric cancer in Japan. Asian J Endosc Surg. 2015 May;8(2):125-9. doi: 10.1111/ases.12171. Epub 2015 Feb 10. Review.</citation>
    <PMID>25676458</PMID>
  </reference>
  <reference>
    <citation>Lee JH, Nam BH, Ryu KW, Ryu SY, Park YK, Kim S, Kim YW. Comparison of outcomes after laparoscopy-assisted and open total gastrectomy for early gastric cancer. Br J Surg. 2015 Nov;102(12):1500-5. doi: 10.1002/bjs.9902. Epub 2015 Sep 23.</citation>
    <PMID>26398912</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol. 2016 Apr 20;34(12):1350-7. doi: 10.1200/JCO.2015.63.7215. Epub 2016 Feb 22.</citation>
    <PMID>26903580</PMID>
  </reference>
  <reference>
    <citation>Jung DH, Son SY, Park YS, Shin DJ, Ahn HS, Ahn SH, Park DJ, Kim HH. The learning curve associated with laparoscopic total gastrectomy. Gastric Cancer. 2016 Jan;19(1):264-72. doi: 10.1007/s10120-014-0447-y. Epub 2014 Dec 7.</citation>
    <PMID>25481705</PMID>
  </reference>
  <reference>
    <citation>Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. doi: 10.1097/SLA.0000000000001346.</citation>
    <PMID>26352529</PMID>
  </reference>
  <reference>
    <citation>Huang CM, Zhang JR, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Chen QY. A 346 case analysis for laparoscopic spleen-preserving no.10 lymph node dissection for proximal gastric cancer: a single center study. PLoS One. 2014 Sep 29;9(9):e108480. doi: 10.1371/journal.pone.0108480. eCollection 2014.</citation>
    <PMID>25264673</PMID>
  </reference>
  <reference>
    <citation>Kurokawa Y, Katai H, Fukuda H, Sasako M; Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group. Phase II study of laparoscopy-assisted distal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group Study JCOG0703. Jpn J Clin Oncol. 2008 Jul;38(7):501-3. doi: 10.1093/jjco/hyn055. Epub 2008 Jun 26.</citation>
    <PMID>18586666</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>December 30, 2016</last_update_submitted>
  <last_update_submitted_qc>December 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Yihong Sun</investigator_full_name>
    <investigator_title>Clinical Professor,Department of General Surgery, Zhongshan Hospital</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Laparoscopic total gastrectomy</keyword>
  <keyword>Open total gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

